Prescription drug · NDA
Wegovy (semaglutide) NDC 50090-5824
Semaglutide .25 mg/.5mL · Injection, Solution · Subcutaneous · A-S Medication Solutions
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 50090-5824-0 | 50090582400 | 4 SYRINGE, PLASTIC in 1 CARTON (50090-5824-0) / .5 mL in 1 SYRINGE, PLASTICMarketed from Oct 25, 2021 |
How the 11-digit form is made: The package segment has 1 digit, so one leading zero is added to it (5-4-1 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Wegovy
- Generic name (nonproprietary)
- semaglutide
- Active ingredients
- Semaglutide — .25 mg/.5mL
- Dosage form
- Injection, Solution
- Route
- Subcutaneous
- Labeler
- A-S Medication Solutions
- Product type
- Prescription drug
- Marketing category
- NDA — New Drug ApplicationApplication NDA 215256
- Marketing start
- Listing expires
- Other FDA classes
- Glucagon-Like Peptide 1 (Chemical structure)Glucagon-like Peptide-1 (GLP-1) Agonists (Mechanism)
- Identifiers
- Product ID 50090-5824_58b8887c-a572-4a74-ad0b-1049d388e206SPL ID 58b8887c-a572-4a74-ad0b-1049d388e206SPL set ID f5e548d0-cc79-4c34-a3f5-e20a5b8b6564RxCUI 2553501, 2553506UNII 53AXN4NNHX
- Pharmacologic class
- GLP-1 Receptor Agonist
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeMed-Code curated
No drug-specific HCPCS code in Med-Code’s directory for this product.
Med-Code's directory has no drug-specific HCPCS code for Wegovy. It is usually self-administered and billed by NDC through a pharmacy benefit. Wegovy tablets are pharmacy-dispensed and have no HCPCS code.
If a payer accepts an unclassified code for it in a clinical setting, that would be J3490 (Unclassified drugs), with the NDC, quantity and often the invoice. Acceptance varies by payer.
- Administration
Drug administration (CPT 96360–96549)
When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.
- NDC on a medical claim
N450090582400followed by a unit qualifier and the quantityPackage 50090-5824-00. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective . This label includes a boxed warning.
Indications (excerpt from the label)
WEGOVY is indicated in combination with a reduced calorie diet and increased physical activity: • to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight. • to reduce excess body weight and maintain weight reduction long term in: o Adults and pediatric patients aged 12 years and older with obesity o Adults with overweight in the presence of at least one weight-related comorbid condition. Limitations of Use • WEGOVY contains semaglutide. Coadministration with other semaglutide-containing products or with any other GLP-1 receptor agon…
Excerpt only. Read the full label for complete information.
Other NDCs under NDA 215256
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Wegovysemaglutide | Semaglutide 1 mg/.5mL | Injection, SolutionSubcutaneous | Novo Nordisk Pharmaceutical Industries, LP | 0169-4501 |
| Wegovysemaglutide | Semaglutide .5 mg/.5mL | Injection, SolutionSubcutaneous | Novo Nordisk Pharmaceutical Industries, LP | 0169-4505 |
| Wegovysemaglutide | Semaglutide 1.7 mg/.75mL | Injection, SolutionSubcutaneous | Novo Nordisk Pharmaceutical Industries, LP | 0169-4517 |
| Wegovysemaglutide | Semaglutide 2.4 mg/.75mL | Injection, SolutionSubcutaneous | Novo Nordisk Pharmaceutical Industries, LP | 0169-4524 |
| Wegovysemaglutide | Semaglutide .25 mg/.5mL | Injection, SolutionSubcutaneous | Novo Nordisk Pharmaceutical Industries, LP | 0169-4525 |
| Wegovysemaglutide | Semaglutide 7.2 mg/.75mL | Injection, SolutionSubcutaneous | Novo Nordisk Pharmaceutical Industries, LP | 0169-4572 |
| Wegovysemaglutide | Semaglutide 3.2 mg/mL | Injection, SolutionSubcutaneous | Novo Nordisk Pharmaceutical Industries, LP | 0169-4915 |
- Source
- FDA NDC Directory via openFDA; FDA SPL via openFDA and DailyMed; Med-Code HCPCS directory (curated)
- openFDA data updated
Med-Code stores this record for up to 24 hours before requesting it again.
Reference information only. Verify codes and billing rules against the applicable payer and official source before submitting a claim. How Med-Code handles data.